ATE202849T1 - Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl- antikörperzubereitung - Google Patents

Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl- antikörperzubereitung

Info

Publication number
ATE202849T1
ATE202849T1 AT95917540T AT95917540T ATE202849T1 AT E202849 T1 ATE202849 T1 AT E202849T1 AT 95917540 T AT95917540 T AT 95917540T AT 95917540 T AT95917540 T AT 95917540T AT E202849 T1 ATE202849 T1 AT E202849T1
Authority
AT
Austria
Prior art keywords
hnl
pct
human neutrophil
antibody preparation
diagnostic marker
Prior art date
Application number
AT95917540T
Other languages
English (en)
Inventor
Per Venge
Original Assignee
Pharmacia Diagnostics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20393731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE202849(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Diagnostics Ab filed Critical Pharmacia Diagnostics Ab
Application granted granted Critical
Publication of ATE202849T1 publication Critical patent/ATE202849T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95917540T 1994-04-21 1995-04-21 Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl- antikörperzubereitung ATE202849T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9401351A SE9401351D0 (sv) 1994-04-21 1994-04-21 A method for diagnosis
PCT/SE1995/000439 WO1995029404A1 (en) 1994-04-21 1995-04-21 Use of human neutrophil lipocalin (hnl) as a diagnostic marker and anti-hnl-antibody preparation

Publications (1)

Publication Number Publication Date
ATE202849T1 true ATE202849T1 (de) 2001-07-15

Family

ID=20393731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95917540T ATE202849T1 (de) 1994-04-21 1995-04-21 Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl- antikörperzubereitung

Country Status (10)

Country Link
US (1) US6136526A (de)
EP (1) EP0756708B1 (de)
JP (1) JP3544544B2 (de)
AT (1) ATE202849T1 (de)
AU (1) AU2355195A (de)
DE (1) DE69521608T2 (de)
DK (1) DK0756708T3 (de)
ES (1) ES2160709T3 (de)
SE (1) SE9401351D0 (de)
WO (1) WO1995029404A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1143246A4 (de) * 1998-12-28 2004-11-24 Advance Kk System zum identifizieren von mikroorganismen
FI115165B (fi) 2001-06-04 2005-03-15 Aboatech Ab Oy Menetelmä infektion laadun määrittämiseksi
US20030119209A1 (en) * 2001-12-21 2003-06-26 Kaylor Rosann Marie Diagnostic methods and devices
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
EP2272566A3 (de) 2003-08-18 2013-01-02 MedImmune, LLC Humanisierung von antikörpern
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
ES2818028T3 (es) * 2004-12-20 2021-04-09 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
PL2035835T3 (pl) 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
WO2008017306A1 (en) 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
WO2008113363A1 (en) * 2007-03-21 2008-09-25 Bioporto Diagnostics A/S Diagnostic test for renal injury
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
ES2475990T5 (es) * 2007-11-15 2017-07-06 Bioporto Diagnostics A/S Uso diagnóstico de formas moleculares individuales de un biomarcador
EP2257813A4 (de) * 2008-03-12 2011-11-02 Univ Columbia Ngal mit hohem molekulargewicht als biomarker für chronische nierenerkrankung
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
KR101939964B1 (ko) 2008-11-21 2019-01-18 퓨처 메디칼 다이아그노스틱스 코 엘티디 급성 신장 손상의 발견 또는 감시 방법, 장치 및 키트
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
US9709565B2 (en) 2010-04-21 2017-07-18 Memed Diagnostics Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
NL2007112C2 (en) 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
CN108802385B (zh) 2012-02-09 2022-02-08 米密德诊断学有限公司 用于诊断感染的标记和决定因素和其使用方法
EP2925337B1 (de) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutante ngal-proteine und verwendungen davon
BR112017002884A2 (pt) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
RU2758608C2 (ru) * 2014-11-19 2021-11-01 Конинклейке Филипс Н.В. Способ диагностики с использованием hnl
CN107209184B (zh) 2014-12-11 2020-04-24 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
EP3423590A4 (de) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. Rna-determinanten zur unterscheidung zwischen bakteriellen und viralen infektionen
IL294121B2 (en) 2016-03-03 2023-09-01 Memed Diagnostics Ltd An RNA test to diagnose the type of infection
WO2018001932A1 (en) 2016-06-30 2018-01-04 Koninklijke Philips N.V. Device, system and method for detecting an analyte in a body fluid sample containing a plurality of cells
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
CA3027341A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2024246048A1 (en) 2023-06-01 2024-12-05 P & M Venge Ab Specific detection of homodimeric hnl
CN119375492B (zh) * 2024-12-27 2025-05-30 北京水木翼锋诊断技术有限公司 Hnl在制备用于鉴定血流感染的试剂中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US5200319A (en) * 1989-10-27 1993-04-06 The General Hospital Corporation Diagnosis of glomerulonephritis

Also Published As

Publication number Publication date
EP0756708A1 (de) 1997-02-05
SE9401351D0 (sv) 1994-04-21
JP3544544B2 (ja) 2004-07-21
JPH09512630A (ja) 1997-12-16
DE69521608D1 (de) 2001-08-09
EP0756708B1 (de) 2001-07-04
AU2355195A (en) 1995-11-16
WO1995029404A1 (en) 1995-11-02
DE69521608T2 (de) 2002-05-08
DK0756708T3 (da) 2001-10-29
US6136526A (en) 2000-10-24
ES2160709T3 (es) 2001-11-16

Similar Documents

Publication Publication Date Title
DE69521608D1 (de) Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl-antikörperzubereitung
Geivelis et al. Measurements of interleukin‐6 in gingival crevicular fluid from adults with destructive periodontal disease
Wilton et al. Interleukin‐1 beta (IL‐1β) levels in gingival crevicular fluid from adults with previous evidence of destructive periodontitis: A cross sectional study
Plagnat et al. Elastase, α2‐macroglobulin and alkaline phosphatase in crevicular fluid from implants with and without periimplantitis
Kido et al. Calprotectin in gingival crevicular fluid correlates with clinical and biochemical markers of periodontal disease
Hyman et al. The predictive value of endodontic diagnostic tests
Johnston Relationships between body composition and anthropometry
Balli et al. Assessment of periostin levels in serum and gingival crevicular fluid of patients with periodontal disease
Perinetti et al. Gingival crevicular fluid alkaline phosphatase activity as a non‐invasive biomarker of skeletal maturation
George et al. Detection of root resorption using dentin and bone markers
DE3581871D1 (de) Verwendung ferromagnetischer teilchen in kontrastmitteln fuer nmr-bild- und kontrastmittel.
Kropf et al. Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases.
Bostanci et al. Tumor necrosis factor-α-converting enzyme (TACE) levels in periodontal diseases
Beaird et al. Incidence of hepatitis C in lichen planus
Yadav et al. Effect of periodontal therapy on lactoferrin levels in gingival crevicular fluid
Sarlati et al. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in gingival crevicular fluid
Melamed et al. Type A behavior, tension, and ambulatory cardiovascular reactivity in workers exposed to noise stress.
Sharma et al. Plasma and crevicular fluid osteopontin levels in periodontal health and disease
Hannigan et al. Soluble cell adhesion molecules in gingival crevicular fluid in periodontal health and disease
Fragkioudakis et al. Diagnostic accuracy of active MMP-8 point-of-care test in peri-implantitis
Santavirta et al. Sense of coherence and outcome of low-back surgery: 5-year follow-up of 80 patients
Meyle Neutrophil chemotaxis and serum concentration of tumor-necrosis-factor-α (TNFA).
Streckfus et al. Aging and salivary cytokine concentrations as predictors of whole saliva flow rates among women: a preliminary study
Guo et al. Associations of salivary BPIFA1 protein in chronic periodontitis patients with type 2 diabetes mellitus
Berglundh et al. Some local and systemic immunological features of prepubertal periodontitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name